Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

AJ Cooper, LV Sequist, JJ Lin - Nature reviews Clinical oncology, 2022‏ - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Y Yang, S Li, Y Wang, Y Zhao, Q Li - Signal transduction and targeted …, 2022‏ - nature.com
Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Targeting apoptosis in cancer therapy

BA Carneiro, WS El-Deiry - Nature reviews Clinical oncology, 2020‏ - nature.com
For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Combining epigenetic drugs with other therapies for solid tumours—past lessons and future promise

D Morel, D Jeffery, S Aspeslagh, G Almouzni… - Nature Reviews …, 2020‏ - nature.com
Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …

The double-edge sword of autophagy in cancer: from tumor suppression to pro-tumor activity

R Chavez-Dominguez, M Perez-Medina… - Frontiers in …, 2020‏ - frontiersin.org
During tumorigenesis, cancer cells are exposed to a wide variety of intrinsic and extrinsic
stresses that challenge homeostasis and growth. Cancer cells display activation of distinct …

Understanding and targeting resistance mechanisms in NSCLC

J Rotow, TG Bivona - Nature Reviews Cancer, 2017‏ - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

RNA splicing dysregulation and the hallmarks of cancer

RK Bradley, O Anczuków - Nature Reviews Cancer, 2023‏ - nature.com
Dysregulated RNA splicing is a molecular feature that characterizes almost all tumour types.
Cancer-associated splicing alterations arise from both recurrent mutations and altered …

Antitumour immunity regulated by aberrant ERBB family signalling

S Kumagai, S Koyama, H Nishikawa - Nature Reviews Cancer, 2021‏ - nature.com
Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: a hospital‐based study

K Sunami, H Ichikawa, T Kubo, M Kato… - Cancer …, 2019‏ - Wiley Online Library
Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide
clinical management by providing information about actionable gene aberrations that have …

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

NCP Cross, T Ernst, S Branford, JM Cayuela… - Leukemia, 2023‏ - nature.com
From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …